 |
|
|
| |
Pan-genotypic Hepatitis C Treatment With Glecaprevir+ Pibrentasvir Resulted in Improvement in Cardiovascular and Metabolic Extrahepatic Manifestations and Stable Renal Function: Results From Phase 3 Clinical Trials
|
| |
| |
Reported by Jules Levin
AASLD - Presented at the American Association for The study of Liver Diseases (AASLD), October 20 -24, 2017, Washington DC, USA
Tram T. Tran,1 Darshan Mehta,2,3Federico J. Mensa,3Caroline Park,3Yuri Sanchez Gonzalez3
1Cedars-Sinai Medical Center, Los Angeles, California, United States; 2Schaeffer Center for Health Policy and Economics, University of Southern California, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
